Stefan prosecutes and provides strategic counseling on U.S. and foreign patent portfolios in the chemical and pharmaceutical industries. His experience also includes assisting with Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act, inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO), and disputes in district courts across the country.
Prior to joining Fenwick, Stefan worked as an associate for a large intellectual property firm, where his practice focused on strategic counseling, prosecution, and patent litigation, primarily in the chemical and pharmaceutical fields.
Stefan also completed a post-doctoral training at Memorial Sloan Kettering Cancer Center. His work included several projects aimed at the discovery and development of heat shock protein 90 (Hsp90), Hsp70, glucose-regulated protein 94 inhibitors, and the design and synthesis of chemical probes for the biological evaluation of these targets.
Stefan’s graduate dissertation research focused on the design, synthesis, and evaluation of human aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing. Stefan has a wide range of technical experience, including the areas of organic and medicinal chemistry, computational chemistry, drug delivery, preclinical drug development, and chemical biology. He has authored or co-authored eighteen journal papers and a book chapter, presented his research at thirteen national and local conferences, and is a co-inventor on many patent applications related to his postdoctoral work.